Brokerages Set Kura Oncology, Inc. (NASDAQ:KURA) Price Target at $25.40

Kura Oncology, Inc. (NASDAQ:KURA) has received an average recommendation of “Moderate Buy” from the twelve analysts that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $25.40.

A number of analysts have weighed in on the company. Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a research report on Monday, August 24th. Jefferies Financial Group set a $24.00 price objective on Kura Oncology in a report on Thursday, May 28th. Morgan Stanley set a $24.00 price objective on Kura Oncology in a research note on Monday, August 24th. CLSA set a $24.00 target price on Kura Oncology in a research report on Thursday, June 4th. Finally, Citizens Jmp reiterated a “market outperform” rating and set a $24.00 price target on shares of Kura Oncology in a report on Monday, August 24th.

Insider Buying and Selling

In related news, insider Teresa Bair sold 31,487 shares of Kura Oncology stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $12.63, for a total value of $397,680.81. Following the transaction, the insider owned 195,444 shares in the company, valued at $2,468,457.72. This trade represents a 13.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Brian T. Powl sold 4,345 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $11.89, for a total transaction of $51,662.05. Following the transaction, the insider directly owned 169,269 shares of the company’s stock, valued at approximately $2,012,608.41. This represents a 2.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Kura Oncology

Institutional investors have recently made changes to their positions in the business. IFP Advisors Inc boosted its stake in Kura Oncology by 115.3% during the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after purchasing an additional 1,284 shares during the period. Allworth Financial LP increased its position in Kura Oncology by 59.9% in the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after buying an additional 1,553 shares during the period. EverSource Wealth Advisors LLC increased its position in Kura Oncology by 49.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock worth $60,000 after buying an additional 1,888 shares during the period. Pictet Asset Management Holding SA acquired a new position in shares of Kura Oncology during the first quarter worth approximately $96,000. Finally, E Fund Management Co. Ltd. acquired a new position in shares of Kura Oncology during the second quarter worth approximately $132,000.

Kura Oncology Stock Performance

KURA stock opened at $11.73 on Wednesday. The firm has a 50 day moving average of $11.21 and a two-hundred day moving average of $10.06. Kura Oncology has a 12 month low of $7.36 and a 12 month high of $13.90. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of -3.48 and a beta of 0.44. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.11. The business had revenue of $20.87 million for the quarter, compared to the consensus estimate of $20.16 million. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. As a group, equities analysts anticipate that Kura Oncology will post -3.25 EPS for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.

Kura’s leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.